Apellis Pharmaceuticals Inc.(APLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

APLS Apellis Pharmaceuticals Inc.

Market Closed 02-06 16:00:00 EST

23.49

+0.93

+4.12%

盘后23.49

+0.000.00%

16:10 EST

High23.58	Low22.57	Vol1.82M
Open22.68	D1 Closing22.56	Amplitude4.48%
Mkt Cap2.97B	Tradable Cap1.84B	Total Shares126.53M
T/O42.57M	T/O Rate2.34%	Tradable Shares78.12M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"APLS","market":"US","secType":"STK","nameCN":"Apellis Pharmaceuticals Inc.","latestPrice":23.49,"timestamp":1770411600000,"preClose":22.56,"halted":0,"volume":1824965,"hourTrading":{"tag":"盘后","latestPrice":23.49,"preClose":23.49,"latestTime":"16:10 EST","volume":11854,"amount":278448.46,"timestamp":1770412204695,"change":0,"changeRate":0,"amplitude":0.000851},"delay":0,"changeRate":0.04122340425531914,"floatShares":78119932,"shares":126525218,"eps":0.35814,"marketStatus":"Market Closed","change":0.93,"latestTime":"02-06 16:00:00 EST","open":22.68,"high":23.58,"low":22.57,"amount":42571624.088418,"amplitude":0.04477,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.35814,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1510203600000,"exchange":"NASDAQ","adjPreClose":22.56,"preHourTrading":{"tag":"盘前","latestPrice":22.68,"preClose":22.56,"latestTime":"09:29 EST","volume":18438,"amount":422026.220406,"timestamp":1770388199999,"change":0.12,"changeRate":0.005319,"amplitude":0.025709},"postHourTrading":{"tag":"盘后","latestPrice":23.49,"preClose":23.49,"latestTime":"16:10 EST","volume":11854,"amount":278448.46,"timestamp":1770412204695,"change":0,"changeRate":0,"amplitude":0.000851},"volumeRatio":0.3100931847036236,"impliedVol":0.5118,"impliedVolPercentile":0.2151},"requestUrl":"/m/hq/s/APLS/wiki","defaultTab":"wiki","newsList":[{"id":"2607071746","title":"How Empaveli’s Rapid Uptake and Q4 2025 Revenue Momentum Will Impact Apellis Pharmaceuticals (APLS) Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2607071746","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607071746?lang=en_us&edition=fundamental","pubTime":"2026-01-31 16:33","pubTimestamp":1769848420,"startTime":"0","endTime":"0","summary":"In recent days, Apellis Pharmaceuticals reported strong momentum for its complement inhibitor Empaveli, including preliminary Q4 2025 U.S. net product revenue of about US$35.00 million, reflecting year-over-year growth and rapid uptake in treating paroxysmal nocturnal hemoglobinuria and other rare conditions with high unmet medical needs.\nInvestor attention has also been drawn to analyst commentary highlighting Empaveli’s early market penetration and underappreciated commercial potential...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apls/apellis-pharmaceuticals/news/how-empavelis-rapid-uptake-and-q4-2025-revenue-momentum-will","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apls/apellis-pharmaceuticals/news/how-empavelis-rapid-uptake-and-q4-2025-revenue-momentum-will","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["APLS","ISBC"],"gpt_icon":0},{"id":"2606871145","title":"Apellis Pharmaceuticals Initiated at Equal-Weight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2606871145","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606871145?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:23","pubTimestamp":1769606580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/APLS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 28, 2026 08:23 ET (13:23 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","BK4588","LU1093756168.USD","APLS","BK4139","BK4505","BK4585"],"gpt_icon":0},{"id":"2606771572","title":"Barclays Initiates Coverage on Apellis Pharmaceuticals With Equal Weight Rating, $24 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2606771572","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606771572?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:15","pubTimestamp":1769602509,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals (APLS) has an average rating of overweight and mean price target of $33.95, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["APLS","BK4505","BK4139","BK4588","LU1093756168.USD","LU1093756325.SGD","BK4585"],"gpt_icon":0},{"id":"2606593547","title":"S&P Dow Jones Indices: TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400","url":"https://stock-news.laohu8.com/highlight/detail?id=2606593547","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606593547?lang=en_us&edition=fundamental","pubTime":"2026-01-28 07:04","pubTimestamp":1769555060,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nFWN3YS16C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APLS","LU1093756325.SGD","BK4505","LU1093756168.USD","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"2605882732","title":"Apellis CEO Cedric Francois Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605882732","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605882732?lang=en_us&edition=fundamental","pubTime":"2026-01-24 05:10","pubTimestamp":1769202611,"startTime":"0","endTime":"0","summary":"Cedric Francois, Chief Executive Officer of Apellis Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260123:nNDL3WGXZx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Apellis CEO Cedric Francois Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4588","LU1093756325.SGD","LU1093756168.USD","APLS","BK4505"],"gpt_icon":0},{"id":"2605899405","title":"Wedbush Lowers Price Target on Apellis Pharmaceuticals to $20 From $22, Keeps Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2605899405","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605899405?lang=en_us&edition=fundamental","pubTime":"2026-01-23 22:12","pubTimestamp":1769177547,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals (APLS) has an average rating of overweight and mean price target of $34.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","LU1093756168.USD","BK4505","LU1093756325.SGD","APLS","BK4139","BK4585"],"gpt_icon":0},{"id":"2605438050","title":"Apellis Pharmaceuticals General Counsel David Watson Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605438050","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605438050?lang=en_us&edition=fundamental","pubTime":"2026-01-22 05:08","pubTimestamp":1769029737,"startTime":"0","endTime":"0","summary":"David O. Watson, General Counsel of Apellis Pharmaceuticals Inc., reported a disposal of common shares of Apellis Pharmaceuticals Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 21, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL5K8sdm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Apellis Pharmaceuticals General Counsel David Watson Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4585","BK4588","BK4139","LU1093756325.SGD","LU1093756168.USD","APLS"],"gpt_icon":0},{"id":"2605843567","title":"How Investors May Respond To Apellis Pharmaceuticals (APLS) Balancing EMPAVELI’s FDA Win With Slow Rare-Disease Uptake","url":"https://stock-news.laohu8.com/highlight/detail?id=2605843567","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605843567?lang=en_us&edition=fundamental","pubTime":"2026-01-22 02:35","pubTimestamp":1769020504,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals recently secured US FDA approval for EMPAVELI to treat the rare kidney diseases C3 glomerulopathy and IC-MPGN, the first and only approved therapy for these conditions, while facing slower-than-hoped patient uptake and flat SYFOVRE sales due to access and reimbursement hurdles.\nThis combination of a major regulatory win with muted early commercial traction highlights the tension between scientific success and the practical realities of rare-disease drug...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apls/apellis-pharmaceuticals/news/how-investors-may-respond-to-apellis-pharmaceuticals-apls-ba","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apls/apellis-pharmaceuticals/news/how-investors-may-respond-to-apellis-pharmaceuticals-apls-ba","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","LU1093756325.SGD","BK4211","BK4588","ISBC","BK4585","APLS","BK4505","LU1093756168.USD"],"gpt_icon":0},{"id":"2605489128","title":"Apellis Valuation Undervalues Empaveli Opportunity in Rare Kidney Disease, BofA Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2605489128","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605489128?lang=en_us&edition=fundamental","pubTime":"2026-01-22 00:19","pubTimestamp":1769012356,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals' (APLS) current valuation does not fully reflect the commercial opportunity for Empaveli in rare kidney diseases such as C3 glomerulopathy (C3G) or immune-complex membranoproli","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4585","BK4588","LU1093756325.SGD","LU1093756168.USD","APLS","BK4505"],"gpt_icon":0},{"id":"2605872107","title":"BofA Securities Upgrades Apellis Pharmaceuticals to Buy From Neutral, $28 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2605872107","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605872107?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:10","pubTimestamp":1769001051,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals (APLS) has an average rating of overweight and mean price target of $34.61, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4505","BK4139","BK4585","APLS","LU1093756168.USD","LU1093756325.SGD","BK4588"],"gpt_icon":0},{"id":"2605091001","title":"Apellis Pharmaceuticals Shares Add 3.7% Premarket After Bofa Global Research Upgrades to Buy From Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=2605091001","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605091001?lang=en_us&edition=fundamental","pubTime":"2026-01-21 19:48","pubTimestamp":1768996098,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nL4N3YM11N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1093756168.USD","BK4585","BK4505","LU1093756325.SGD","BK4139","BK4588","APLS"],"gpt_icon":0},{"id":"2605110991","title":"Apellis Pharmaceuticals Inc : Bofa Global Research Raises to Buy From Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=2605110991","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605110991?lang=en_us&edition=fundamental","pubTime":"2026-01-21 19:44","pubTimestamp":1768995856,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nFWN3YM118:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","LU1093756325.SGD","BK4139","BK4588","APLS","LU1093756168.USD","BK4585"],"gpt_icon":0},{"id":"2605058821","title":"Apellis Pharmaceuticals Raised to Buy From Neutral by B of A Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2605058821","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605058821?lang=en_us&edition=fundamental","pubTime":"2026-01-21 18:46","pubTimestamp":1768992360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/APLS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 21, 2026 05:46 ET (10:46 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","LU1093756168.USD","BK4588","BK4139","LU1093756325.SGD","APLS","BK4585"],"gpt_icon":0},{"id":"2605103406","title":"Apellis upgraded to Buy from Neutral at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2605103406","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605103406?lang=en_us&edition=fundamental","pubTime":"2026-01-21 18:25","pubTimestamp":1768991111,"startTime":"0","endTime":"0","summary":"BofA analyst Tazeen Ahmad upgraded Apellis (APLS) to Buy from Neutral with an unchanged price target of $28. The firm believes current valuation le...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apellis-upgraded-to-buy-from-neutral-at-bofa-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apellis-upgraded-to-buy-from-neutral-at-bofa-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","APLS","LU1093756325.SGD","BK4585","BK4588","BK4139","LU1093756168.USD"],"gpt_icon":0},{"id":"2605748201","title":"U.S. RESEARCH ROUNDUP-IBM, KLA, WEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2605748201","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605748201?lang=en_us&edition=fundamental","pubTime":"2026-01-21 16:26","pubTimestamp":1768984001,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-IBM, KLA, WEXJan 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including IBM, KLA and WEX, on Wednesday","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nL4N3YM0NJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARES","ADI","MMM","ACLS","GOOGL","AMDU","AN","AMDG","BFAM","APLS","BKR","AMD","ARDX","ASGN","GGLL","APG","AZN","ACM","ARCB","AMUU","AMDD","DAMD","CZR","CRI","AMDW","AMDY","APLD","AXSM","APD","BHVN","EAT","AMDL","KMX","ABM","BG","AMYY","ARWR","ALB","AME","BOKF","ACVA","BEAM","BRBR","CPB","BA","AMP","AR","AU","ABG","ALGM"],"gpt_icon":1},{"id":"2604003190","title":"RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2604003190","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604003190?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:16","pubTimestamp":1768911405,"startTime":"0","endTime":"0","summary":"In a report released today, Lisa Walter from RBC Capital maintained a Hold rating on Apellis Pharmaceuticals, with a price target of $22.00. Accord...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-apellis-pharmaceuticals-apls-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-apellis-pharmaceuticals-apls-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APLS"],"gpt_icon":0},{"id":"2603199663","title":"Apellis Pharmaceuticals' Partner Sobi Gains EU Approval for Aspaveli in Rare Kidney Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2603199663","media":"MT Newswires Live","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603199663?lang=en_us&edition=fundamental","pubTime":"2026-01-16 21:09","pubTimestamp":1768568997,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals (APLS) partner Sobi said Friday that the European Commission approved Aspaveli (pegcetacoplan) for adults and adolescents aged 12 to 17 with C3 glomerulopathy (C3G) or primary ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["APLS","BK4505","BK4139","BK4156","BK4588","BK7062","BK4585","BK7095","LU1093756168.USD","LU1093756325.SGD","RAS.AU"],"gpt_icon":0},{"id":"2603496026","title":"European Commission Approves Aspaveli by Sobi for Treatment of C3G and Primary IC-MPGN","url":"https://stock-news.laohu8.com/highlight/detail?id=2603496026","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603496026?lang=en_us&edition=fundamental","pubTime":"2026-01-16 19:32","pubTimestamp":1768563170,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Swedish Orphan Biovitrum AB published the original content used to generate this news brief on January 16, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL7kwLpt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APLS","BK4585","BK4588","BK4139","LU1093756325.SGD","BK4505","LU1093756168.USD"],"gpt_icon":0},{"id":"2603350349","title":"Apellis CEO Cedric Francois Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2603350349","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603350349?lang=en_us&edition=fundamental","pubTime":"2026-01-16 05:31","pubTimestamp":1768512701,"startTime":"0","endTime":"0","summary":"Cedric Francois, Chief Executive Officer of Apellis Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 15, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDL2yVwsL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Apellis CEO Cedric Francois Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","LU1093756168.USD","BK4139","APLS","LU1093756325.SGD","BK4585","BK4588"],"gpt_icon":0},{"id":"2603960176","title":"Apellis Pharmaceuticals (APLS) Receives a Buy from Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2603960176","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603960176?lang=en_us&edition=fundamental","pubTime":"2026-01-15 19:36","pubTimestamp":1768476960,"startTime":"0","endTime":"0","summary":"In a report released on January 13, Yigal Nochomovitz from Citi maintained a Buy rating on Apellis Pharmaceuticals, with a price target of $45.00. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/apellis-pharmaceuticals-apls-receives-a-buy-from-citi-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/apellis-pharmaceuticals-apls-receives-a-buy-from-citi-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU1093756168.USD","BK4505","LU1093756325.SGD","APLS","BK4139","BK4585"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.apellis.com","stockEarnings":[{"period":"1week","weight":0.0403},{"period":"1month","weight":-0.1133},{"period":"3month","weight":0.2196},{"period":"6month","weight":-0.0361},{"period":"1year","weight":-0.2222},{"period":"ytd","weight":-0.0649}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0293},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.139},{"period":"ytd","weight":0.0128}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":-0.03559},{"month":2,"riseRate":0.666667,"avgChangeRate":0.033433},{"month":3,"riseRate":0.5,"avgChangeRate":0.022263},{"month":4,"riseRate":0.625,"avgChangeRate":0.039768},{"month":5,"riseRate":0.375,"avgChangeRate":-0.036849},{"month":6,"riseRate":0.75,"avgChangeRate":0.072936},{"month":7,"riseRate":0.625,"avgChangeRate":-0.050758},{"month":8,"riseRate":0.875,"avgChangeRate":0.155594},{"month":9,"riseRate":0.125,"avgChangeRate":-0.147812},{"month":10,"riseRate":0.375,"avgChangeRate":0.006953},{"month":11,"riseRate":0.625,"avgChangeRate":0.128375},{"month":12,"riseRate":0.777778,"avgChangeRate":0.130311}],"exchange":"NASDAQ","name":"Apellis Pharmaceuticals Inc.","nameEN":"Apellis Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Apellis Pharmaceuticals Inc.(APLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Apellis Pharmaceuticals Inc.(APLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Apellis Pharmaceuticals Inc.,APLS,Apellis Pharmaceuticals Inc.股票,Apellis Pharmaceuticals Inc.股票老虎,Apellis Pharmaceuticals Inc.股票老虎国际,Apellis Pharmaceuticals Inc.行情,Apellis Pharmaceuticals Inc.股票行情,Apellis Pharmaceuticals Inc.股价,Apellis Pharmaceuticals Inc.股市,Apellis Pharmaceuticals Inc.股票价格,Apellis Pharmaceuticals Inc.股票交易,Apellis Pharmaceuticals Inc.股票购买,Apellis Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Apellis Pharmaceuticals Inc.(APLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Apellis Pharmaceuticals Inc.(APLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}